Stafloxacin therapy against Mycoplasma genitalium infections

Phase 3

Recruiting

• Conditions: Mycoplasma genitalium; Urithritis, Proctitis, Sexually transmitted infections, Mycoplasma genitalium, Sitafloxacin, Moxifloxacin, Sequential therapy, ParC, GyrA; D045704

• Registration Number: JPRN-jRCTs031230111
• Lead Sponsor: Ando Naokatsu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-06
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

1. Patients provided an informed consent in writing.
2. Patients aged 18 years or older.
3. Patients diagnosed with Mycoplasma genitalium by urine or rectal sample

Exclusion Criteria

1. Individuals with pregnancy
2. Individuals with a history of known hypersensitivity to sitafloxacin, doxycycline or moxifloxacin.
3. Individuals who are judged by their physicians in charge to be ineligible for any reason

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cure rate

Secondary Outcome Measures

Name	Time	Method
Changes of bacterial load after intervention<br>New development of resistant associated mutations after intervention